SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $143,303,475 |
| Positions | 82 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| CONTINEUM THERAPEUTICS | CTNM | CL A | $11,925,151 | 727,587 |
| SHOULDER INNOVATIONS | SI | COMMON STOCK | $8,728,654 | 430,407 |
| ELI LILLY & CO | LLY | COM | $7,621,178 | 6,354 |
| UNITEDHEALTH GRP INC | UNH | COM | $5,500,863 | 13,235 |
| JOHNSON & JOHNSON | JNJ | COM | $4,626,825 | 18,218 |
| ORUKA THERAPEUTICS INC | ORKA | COM | $3,995,903 | 41,987 |
| BIONTECH SE | BNTX | SP ADR | $3,895,910 | 41,869 |
| DEFINIUM THERAPEUTICS INC | DFTX | COM SHS | $3,683,702 | 78,310 |
| DEXCOM INC | DXCM | COM | $3,418,417 | 50,756 |
| ARCUS BIOSCIENCES | RCUS | COM | $3,418,122 | 110,870 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.